Marcos Hortes N Chagas1, Antonio W Zuardi2, Vitor Tumas3, Márcio Alexandre Pena-Pereira3, Emmanuelle T Sobreira3, Mateus M Bergamaschi2, Antonio Carlos dos Santos2, Antonio Lucio Teixeira4, Jaime E C Hallak2, José Alexandre S Crippa2. 1. Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil INCT Translational Medicine (CNPq), São Paulo, Brazil Barretos School of Health Sciences - Dr. Paulo Prata, Barretos, Brazil mchagas@fmrp.usp.br mchagas@facisb.edu.br. 2. Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil INCT Translational Medicine (CNPq), São Paulo, Brazil. 3. Department of Neuroscience and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. 4. Laboratório Interdisciplinar de Investigação Médica, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Abstract
INTRODUCTION:Parkinson's disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons. Although no neuroprotective treatments for PD have been found to date, the endocannabinoid system has emerged as a promising target. METHODS: From a sample of 119 patients consecutively evaluated in a specialized movement disorders outpatient clinic, we selected 21 PD patients without dementia or comorbid psychiatric conditions. Participants were assigned to three groups of seven subjects each who were treated with placebo, cannabidiol (CBD) 75 mg/day or CBD 300 mg/day. One week before the trial and in the last week of treatment participants were assessed in respect to (i) motor and general symptoms score (UPDRS); (ii) well-being and quality of life (PDQ-39); and (iii) possible neuroprotective effects (BDNF and H(1)-MRS). RESULTS: We found no statistically significant differences in UPDRS scores, plasma BDNF levels or H(1)-MRS measures. However, the groups treated with placebo and CBD 300 mg/day had significantly different mean total scores in the PDQ-39 (p = 0.05). CONCLUSIONS: Our findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives are required before definitive conclusions can be drawn.
RCT Entities:
INTRODUCTION:Parkinson's disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons. Although no neuroprotective treatments for PD have been found to date, the endocannabinoid system has emerged as a promising target. METHODS: From a sample of 119 patients consecutively evaluated in a specialized movement disordersoutpatient clinic, we selected 21 PDpatients without dementia or comorbid psychiatric conditions. Participants were assigned to three groups of seven subjects each who were treated with placebo, cannabidiol (CBD) 75 mg/day or CBD 300 mg/day. One week before the trial and in the last week of treatment participants were assessed in respect to (i) motor and general symptoms score (UPDRS); (ii) well-being and quality of life (PDQ-39); and (iii) possible neuroprotective effects (BDNF and H(1)-MRS). RESULTS: We found no statistically significant differences in UPDRS scores, plasma BDNF levels or H(1)-MRS measures. However, the groups treated with placebo and CBD 300 mg/day had significantly different mean total scores in the PDQ-39 (p = 0.05). CONCLUSIONS: Our findings point to a possible effect of CBD in improving quality of life measures in PDpatients with no psychiatric comorbidities; however, studies with larger samples and specific objectives are required before definitive conclusions can be drawn.
Authors: José Alexandre S Crippa; Antonio Waldo Zuardi; Jaime Eduardo Cecílio Hallak; Bruna Miyazawa; Sandra Aparecido Bernardo; Carmem Maria Donaduzzi; Silvane Guzzi; Wagner Alex Jann Favreto; Alline Campos; Maria Eugênia C Queiroz; Francisco S Guimarães; Patrícia Moura da Rosa Zimmermann; Letícia Mello Rechia; Volnei Jose Tondo Filho; Liberato Brum Junior Journal: Cannabis Cannabinoid Res Date: 2020-02-27
Authors: José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-01-31 Impact factor: 5.270
Authors: Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper Journal: Pharmacol Biochem Behav Date: 2020-10-18 Impact factor: 3.533